Reinventing the fight against bacteria, one phage at a time.

  Laurel Robbins ’23 awarded coveted national fellowship to fund PhD work When Laurel Robbins ’23 learned she received the 2025 National Science Foundation Graduate Research Fellowship Program Award, she was surrounded by  friends, all anxiously awaiting the results. “Finding out I was awarded this fellowship was extremely exciting,” Robbins said. “Once I found out I had been awarded the fellowship, the first people I told were my parents, who are my biggest supporters.”   Robbins, who majored in biochemistry and molecular biology at the College, is currently a PhD candidate in biochemistry at the University of Colorado Boulder. Winning this prestigious fellowship means she has secure funding toward her tuition, stipend, and fees for the next three years of her graduate studies. In the current         scientific funding climate, having this security in her position is a major relief for Robbins. The fellowship will also broaden her scientific netw...

Could zoo poo hold the key to fighting infection? Samples were collected from each of the animals at Dudley Zoo (BBC, Copyright) Zoo poo could be the source for exciting developments in medical treatments, according to scientists. They have been busy analysing dung samples from nearly every animal at Dudley Zoo in their search for potential new ways to tackle infections in patients. Inside animal droppings you can find very special viruses called bacteriophages, or phages for short. I asked Dr Andrew Millard from the University of Leicester, who is leading the project, why his team was so interested in them. The dung samples could help find new ways of fighting bacterial infection, scientists say (BBC, Copyright) " We're running out of antibiotics to treat infections, so we need new treatments," he said. "And one of these potential treatments are bacteriophages because they're extremely efficient at killing bacteria." Dr Millard and his team are building up ...

Mini-Symposium Announcement Infection and Cell Biology Meets Virology August 29, 2025 | Tromsø, Norway Hosted by : Christine Hanssen Rinaldo (UiT) and Hans H. Hirsch (University of Basel) Introduction The Department of Medical Biology at UiT The Arctic University of Norway, in collaboration with the University of Basel, is proud to host a focused one-day mini-symposium on Infection, Cell Biology, and Virology , taking place on August 29, 2025 in Tromsø . This informal but high-level event is open to all researchers and students with an interest in virology, immunology, infectious disease, and molecular cell biology. The goal is simple yet crucial: to create a space for cross-institutional exchange, scientific discussion, and the fostering of future collaborations. A Highlight Not to Miss: Phages and the Liver – A Hidden Frontier Among the many compelling talks on polyomaviruses, immune responses, and transplant-related virology, a particularly innovative and timely highlight ...

International Conference Announcement ONE HEALTH, ONE SOLUTION: Bacteriophages Against AMR Date: January 17, 2026 Location: Department of Biological Sciences, BITS Pilani, K.K. Birla Goa Campus, Goa, India Taken from :  https://www.bits-pilani.ac.in/goa/ohos2026/ Introduction The Department of Biological Sciences at BITS Pilani, K.K. Birla Goa Campus, is pleased to announce an international conference on a topic of critical global importance: "ONE HEALTH, ONE SOLUTION: Bacteriophages Against AMR." This one-day event will serve as a dynamic forum for scientists, researchers, clinicians, regulatory professionals, and industry stakeholders to collaborate on innovative solutions to one of the most pressing public health crises of our time— Antimicrobial Resistance (AMR) . Conference Scope Antimicrobial Resistance is a growing threat that transcends human health, impacting animals, agriculture, and the environment. Aligned with the One Health philosophy, this conferenc...

Cytophage secures Health Canada validation for OvaPhage and PhageFend products for use in food safety Taken from :  https://cytophage.com/wp-content/uploads/2024/08/cytophage-news-image-1.jpg Cytophage receives Letters of No Objection (LONO) from Health Canada for two of its cutting-edge bacteriophage products Regulatory milestone accelerates Cytophage’s path to commercialization and broader market access Canada aligns with the EU and US in accepting phage technology, advancing antibiotic-free food solutions WINNIPEG, August 25, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that it is in receipt of two Letters of No Objection (“LONO”) from Health Canada regarding its OvaPhage egg surface product and its PhageFend food surface product, marking a major regulatory milestone that will help pave the way for the introduction of innovative, science-driven solutions to enhance food safety in the Canadian market. The LONO validat...

Phage Therapy in 2025: From Century-Old Cure to Modern Clinical Challenge Phage therapy - the therapeutic use of bacteriophages to treat bacterial infections—has re‑entered the clinical mainstream. Despite a century of use, there is still no centrally approved product in the US or EU. This article reviews the current state of the field in 2025, linking current clinical programs, our curated clinical-trials dataset, and historical practices in Georgia and Poland, and then identifies the infrastructure still needed for broad adoption. Industry Push Toward Clinically Validated Phage Therapy: BiomX and the Road Ahead BiomX (NYSE: PHGE) has entered a pivotal stage with its therapeutic phage programs, by initiating a randomised, double-blind, placebo-controlled Phase 2b trial of BX004 for chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF)(1). The first patient was dosed in July 2025, marking a significant milestone after the earlier Phase 1b/2a study and the publication...